Anguraj Sadanandam

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/1669995/publications.pdf

Version: 2024-02-01

67 papers	10,794 citations	159585 30 h-index	110387 64 g-index
78 all docs	78 docs citations	78 times ranked	18973 citing authors

#	Article	IF	Citations
1	ARAF suppresses ERBB3 expression and metastasis in a subset of lung cancers. Science Advances, 2022, 8, eabk1538.	10.3	4
2	Refining colorectal cancer classification and clinical stratification through a single-cell atlas. Genome Biology, 2022, 23, 113.	8.8	48
3	GREM1 is required to maintain cellular heterogeneity in pancreatic cancer. Nature, 2022, 607, 163-168.	27.8	31
4	Immune landscape, evolution, hypoxia-mediated viral mimicry pathways and therapeutic potential in molecular subtypes of pancreatic neuroendocrine tumours. Gut, 2021, 70, 1904-1913.	12.1	24
5	DNA methylation patterns identify subgroups of pancreatic neuroendocrine tumors with clinical association. Communications Biology, 2021, 4, 155.	4.4	26
6	Differential and longitudinal immune gene patterns associated with reprogrammed microenvironment and viral mimicry in response to neoadjuvant radiotherapy in rectal cancer. , 2021, 9, e001717.		19
7	Prognostic and predictive impact of consensus molecular subtypes and CRCAssigner classifications in metastatic colorectal cancer: a translational analysis of the TRIBE2 study. ESMO Open, 2021, 6, 100073.	4.5	12
8	The 2nd Conference and Workshop of The Cancer Genome Atlas (TCGA) in India: Towards Team Science for Multi-omics Cancer Research in South Asia. Ecancermedicalscience, 2021, 15, ed111.	1.1	2
9	Cannabinoids in the landscape of cancer. Journal of Cancer Research and Clinical Oncology, 2021, 147, 2507-2534.	2.5	53
10	Modulation of pancreatic cancer cell sensitivity to FOLFIRINOX through microRNA-mediated regulation of DNA damage. Nature Communications, 2021, 12, 6738.	12.8	10
11	The molecular biology of pancreatic neuroendocrine neoplasms: Challenges and translational opportunities. Seminars in Cancer Biology, 2020, 61, 132-138.	9.6	16
12	A Machine-Learning Tool Concurrently Models Single Omics and Phenome Data for Functional Subtyping and Personalized Cancer Medicine. Cancers, 2020, 12, 2811.	3.7	0
13	Intratumoral Transcriptome Heterogeneity Is Associated With Patient Prognosis and Sidedness in Patients With Colorectal Cancer Treated With Anti-EGFR Therapy From the CO.20 Trial. JCO Precision Oncology, 2020, 4, 1152-1162.	3.0	6
14	Detection of postoperative plasma circulating tumour DNA and lack of CDX2 expression as markers of recurrence in patients with localised colon cancer. ESMO Open, 2020, 5, e000847.	4.5	21
15	Immunological combination treatment holds the key to improving survival in pancreatic cancer. Journal of Cancer Research and Clinical Oncology, 2020, 146, 2897-2911.	2.5	14
16	A blood transcriptome-based analysis of disease progression, immune regulation, and symptoms in coronavirus-infected patients. Cell Death Discovery, 2020, 6, 141.	4.7	28
17	A blood transcriptome-based analysis of disease progression, immune regulation, and symptoms in coronavirus-infected patients. Cell Death Discovery, 2020, 6, .	4.7	2
18	Consensus molecular subtypes and CRCassigner classifications in metastatic colorectal cancer (mCRC): Prognostic and predictive impact in the TRIBE2 study.. Journal of Clinical Oncology, 2020, 38, 4016-4016.	1.6	6

#	Article	IF	Citations
19	Heterocellular gene signatures reveal luminal-A breast cancer heterogeneity and differential therapeutic responses. Npj Breast Cancer, 2019, 5, 21.	5.2	43
20	Genomic and Transcriptomic Determinants of Therapy Resistance and Immune Landscape Evolution during Anti-EGFR Treatment in Colorectal Cancer. Cancer Cell, 2019, 36, 35-50.e9.	16.8	179
21	Is the tumour microenvironment a critical prognostic factor in early-stage colorectal cancer?. Annals of Oncology, 2019, 30, 1538-1540.	1.2	4
22	Analytical Validation of Multiplex Biomarker Assay to Stratify Colorectal Cancer into Molecular Subtypes. Scientific Reports, 2019, 9, 7665.	3.3	36
23	Benefit from anti-EGFRs in RAS and BRAF wild-type metastatic transverse colon cancer: a clinical and molecular proof of concept study. ESMO Open, 2019, 4, e000489.	4.5	14
24	Context mattersâ€"consensus molecular subtypes of colorectal cancer as biomarkers for clinical trials. Annals of Oncology, 2019, 30, 520-527.	1.2	80
25	ATR Inhibition Potentiates the Radiation-induced Inflammatory Tumor Microenvironment. Clinical Cancer Research, 2019, 25, 3392-3403.	7.0	144
26	Interâ€•and intraâ€tumoural heterogeneity in cancerâ€associated fibroblasts of human pancreatic ductal adenocarcinoma. Journal of Pathology, 2019, 248, 51-65.	4.5	215
27	Suppression of interferon gene expression overcomes resistance to MEK inhibition in KRAS-mutant colorectal cancer. Oncogene, 2019, 38, 1717-1733.	5.9	29
28	Characterization of chemoradiation-induced changes in immune cells and targets for personalized therapy in locally advanced rectal cancer (LARC).. Journal of Clinical Oncology, 2019, 37, 589-589.	1.6	15
29	Patient-derived organoids model treatment response of metastatic gastrointestinal cancers. Science, 2018, 359, 920-926.	12.6	1,199
30	A seven-Gene Signature assay improves prognostic risk stratification of perioperative chemotherapy treated gastroesophageal cancer patients from the MAGIC trial. Annals of Oncology, 2018, 29, 2356-2362.	1.2	32
31	Microenvironmental niche divergence shapes BRCA1-dysregulated ovarian cancer morphological plasticity. Nature Communications, 2018, 9, 3917.	12.8	33
32	polyClustR: defining communities of reconciled cancer subtypes with biological and prognostic significance. BMC Bioinformatics, 2018, 19, 182.	2.6	1
33	Molecular subtypes in cancers of the gastrointestinal tract. Nature Reviews Gastroenterology and Hepatology, 2017, 14, 333-342.	17.8	99
34	A Novel Statistical Method to Diagnose, Quantify and Correct Batch Effects in Genomic Studies. Scientific Reports, 2017, 7, 10849.	3.3	32
35	A rectal cancer feasibility study with an embedded phase III trial design assessing magnetic resonance tumour regression grade (mrTRG) as a novel biomarker to stratify management by good and poor response to chemoradiotherapy (TRIGGER): study protocol for a randomised controlled trial. Trials, 2017, 18, 394.	1.6	72
36	Molecular or Metabolic Reprograming: What Triggers Tumor Subtypes?. Cancer Research, 2016, 76, 5195-5200.	0.9	41

#	Article	IF	Citations
37	Molecular Classification of Colon Cancer: Perspectives for Personalized Adjuvant Therapy. Current Colorectal Cancer Reports, 2016, 12, 296-302.	0.5	1
38	A Cross-Species Analysis in Pancreatic Neuroendocrine Tumors Reveals Molecular Subtypes with Distinctive Clinical, Metastatic, Developmental, and Metabolic Characteristics. Cancer Discovery, 2015, 5, 1296-1313.	9.4	145
39	The consensus molecular subtypes of colorectal cancer. Nature Medicine, 2015, 21, 1350-1356.	30.7	3,596
40	Reconciliation of classification systems defining molecular subtypes of colorectal cancer. Cell Cycle, 2014, 13, 353-357.	2.6	69
41	Reply to Colorectal cancer classification based on gene expression is not associated with FOLFIRI response. Nature Medicine, 2014, 20, 1231-1232.	30.7	5
42	Semaphorin 5A mediated cellular navigation: Connecting nervous system and cancer. Biochimica Et Biophysica Acta: Reviews on Cancer, 2014, 1846, 485-493.	7.4	14
43	Yap1 Activation Enables Bypass of Oncogenic Kras Addiction in Pancreatic Cancer. Cell, 2014, 158, 185-197.	28.9	553
44	A colorectal cancer classification system that associates cellular phenotype and responses to therapy. Nature Medicine, 2013, 19, 619-625.	30.7	831
45	Identification and Characterization of Poorly Differentiated Invasive Carcinomas in a Mouse Model of Pancreatic Neuroendocrine Tumorigenesis. PLoS ONE, 2013, 8, e64472.	2.5	15
46	Secreted semaphorin 5A suppressed pancreatic tumour burden but increased metastasis and endothelial cell proliferation. British Journal of Cancer, 2012, 107, 501-507.	6.4	48
47	Genomic aberrations in normal tissue adjacent to HER2-amplified breast cancers: field cancerization or contaminating tumor cells?. Breast Cancer Research and Treatment, 2012, 136, 693-703.	2.5	15
48	Subtype and pathway specific responses to anticancer compounds in breast cancer. Proceedings of the National Academy of Sciences of the United States of America, 2012, 109, 2724-2729.	7.1	417
49	Subtypes of pancreatic ductal adenocarcinoma and their differing responses to therapy. Nature Medicine, 2011, 17, 500-503.	30.7	1,460
50	A Cross-Species Analysis of a Mouse Model of Breast Cancer-Specific Osteolysis and Human Bone Metastases Using Gene Expression Profiling. BMC Cancer, 2011, 11, 304.	2.6	13
51	Prediction of epigenetically regulated genes in breast cancer cell lines. BMC Bioinformatics, 2010, 11, 305.	2.6	34
52	Small interfering RNAâ€mediated CXCR1 or CXCR2 knockâ€down inhibits melanoma tumor growth and invasion. International Journal of Cancer, 2010, 126, 328-336.	5.1	54
53	High gene expression of semaphorin 5A in pancreatic cancer is associated with tumor growth, invasion and metastasis. International Journal of Cancer, 2010, 127, 1373-1383.	5.1	58
54	Semaphorin 5A promotes angiogenesis by increasing endothelial cell proliferation, migration, and decreasing apoptosis. Microvascular Research, 2010, 79, 1-9.	2.5	81

#	Article	IF	Citations
55	The expression level of HJURP has an independent prognostic impact and predicts the sensitivity to radiotherapy in breast cancer. Breast Cancer Research, 2010, 12, R18.	5.0	115
56	Bioinformatics Analysis to Identify Cell Adhesion Molecules in Cancer. , 2010, , 309-325.		0
57	CXCR1 and CXCR2 enhances human melanoma tumourigenesis, growth and invasion. British Journal of Cancer, 2009, 100, 1638-1646.	6.4	110
58	Small-Molecule Antagonists for CXCR2 and CXCR1 Inhibit Human Melanoma Growth by Decreasing Tumor Cell Proliferation, Survival, and Angiogenesis. Clinical Cancer Research, 2009, 15, 2380-2386.	7.0	136
59	A systems analysis of the chemosensitivity of breast cancer cells to the polyamine analogue PG-11047. BMC Medicine, 2009, 7, 77.	5.5	31
60	Enhanced expression and shedding of receptor activator of NF-Î¹B ligand during tumorâ€“bone interaction potentiates mammary tumor-induced osteolysis. Clinical and Experimental Metastasis, 2009, 26, 797-808.	3.3	15
61	Transforming growth factorâ€Î² signaling at the tumorâ€“bone interface promotes mammary tumor growth and osteoclast activation. Cancer Science, 2009, 100, 71-81.	3.9	58
62	Identification of Semaphorin 5A Interacting Protein by Applying Apriori Knowledge and Peptide Complementarity Related to Protein Evolution and Structure. Genomics, Proteomics and Bioinformatics, 2008, 6, 163-174.	6.9	14
63	Cathepsin G Enhances Mammary Tumorâ€“Induced Osteolysis by Generating Soluble Receptor Activator of Nuclear Factor-Î¹B Ligand. Cancer Research, 2008, 68, 5803-5811.	0.9	84
64	MCAM: A Database to Accelerate the Identification of Functional Cell Adhesion Molecules. Cancer Informatics, 2008, 6, CIN.S341.	1.9	3
65	Identification of Functional Cell Adhesion Molecules with a Potential Role in Metastasis by a Combination ofin vivoPhage Display andin silicoAnalysis. OMICS A Journal of Integrative Biology, 2007, 11, 41-57.	2.0	39
66	Chemokines in tumor angiogenesis and metastasis. Cancer and Metastasis Reviews, 2007, 26, 453-467.	5.9	162
67	Gene expression profiling using a unique murine mammary tumor model reveal role of novel genes regulating tumorâ€stromal interaction in mammary tumorâ€induced osteolysis. FASEB Journal, 2006, 20, A222.	0.5	0